SELENOO

Across TCGA pan-cancer cohorts, SELENOO mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SELENOO data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SELENOO mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SELENOO expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where SELENOO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.798	<.001	58	view →
LUAD	DFS	Median	III,IV	0.485	0.996	.001	27	view →
HNSC	OS	Quartile	III,IV	0.964	0.166	.024	16	view →
UCEC	DFS	Tertile	II,III,IV	0.916	0.392	.011	12	view →
GBM	OS	Median	All	0.841	0.788	.026	3	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
LSCC	OS	Median	All	1.000	0.793	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SELENOO–CCRCC (DFS)

Open the CCRCC breakdown →